Nuvectis Pharma

Nuvectis Pharma, Inc. is a biopharmaceutical company focused on developing targeted therapies for cancer, addressing serious conditions with unmet medical needs in oncology. Our mission is to improve outcomes for cancer patients. Our pipeline currently includes two novel drug candidates: NXP800, an oral small molecule HSF1 pathway inhibitor; and NXP900, an oral small molecule SRC/YES1 kinase inhibitor.